Literature DB >> 8968386

Single-domain angiotensin I converting enzyme (kininase II): characterization and properties.

P A Deddish1, L X Wang, H L Jackman, B Michel, J Wang, R A Skidgel, E G Erdös.   

Abstract

Somatic angiotensin I converting enzyme (ACE; kininase II) has two active sites, in two (N and C) domains. We studied the active centers with separate N-domain ACE (N-ACE), testicular C-domain ACE (germinal ACE) and, as control, renal somatic ACE. Germinal ACE cleaved the nonapeptide bradykinin about two times faster than N-ACE in 20 mM Cl-. Bradykinin1-7 was hydrolyzed further to bradykinin1-5 by N-ACE four times faster in the absence of Cl-, but at 300 mM Cl- the C-domain hydrolyzed it twice as fast. The hematopoietic system regulatory peptide acetyl-Ser-Asp-Lys-Pro was split to two dipeptides by N-ACE, depending on the chloride concentration, 8 to 24 times faster than by germinal ACE; at 100 mM Cl-, the Kcat with N-ACE was eight times higher. One millimolar 1-fluoro-2,4-dinitrobenzene inhibited germinal ACE 96% but it inhibited N-ACE by only 31%. [3H]Ramiprilat was displaced by other unlabeled ACE inhibitors to establish their relative affinities. Captopril had the lowest IC50 (0.5 nM) with N-ACE and the highest IC50 (8.3 nM) with the germinal ACE. The IC50 values of ramiprilat and quinaprilat were about the same with both active sites. The association and dissociation constants of [3H]ramiprilat indicated faster association with and faster dissociation from N-ACE than from germinal ACE. After exposure to alkali or moderate heat, somatic ACE was cleaved by plasmin and kallikrein, releasing N-ACE and apparently inactivating the C-domain. These studies affirm the differences in the activity, stability and inhibition of the two active sites of ACE.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968386

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

2.  RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.

Authors:  V Dive; J Cotton; A Yiotakis; A Michaud; S Vassiliou; J Jiracek; G Vazeux; M T Chauvet; P Cuniasse; P Corvol
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

3.  Kinetic probes for inter-domain co-operation in human somatic angiotensin-converting enzyme.

Authors:  Olga E Skirgello; Peter V Binevski; Vladimir F Pozdnev; Olga A Kost
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

4.  Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domain.

Authors:  Sergei M Danilov; Sergey Kalinin; Zhenlong Chen; Elena I Vinokour; Andrew B Nesterovitch; David E Schwartz; Olivier Gribouval; Marie-Claire Gubler; Richard D Minshall
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

5.  Characterization of dipeptidylcarboxypeptidase of Leishmania donovani: a molecular model for structure based design of antileishmanials.

Authors:  Mirza Saqib Baig; Ashutosh Kumar; Mohammad Imran Siddiqi; Neena Goyal
Journal:  J Comput Aided Mol Des       Date:  2009-12-29       Impact factor: 3.686

6.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06

7.  Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.

Authors:  Geoffrey Masuyer; Ross G Douglas; Edward D Sturrock; K Ravi Acharya
Journal:  Sci Rep       Date:  2015-09-25       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.